Abstract
1 The pharmacokinetics of labetalol were studied in twelve hypertensive patients, ten of whom were not receiving other therapy. 2 Following intravenous administration there was a three- to fourfold variation in terminal elimination half-life, volume of distribution and total plasma clearance. The mean elimination half-life was 3.25 hours. 3 Following oral administration the drug was absorbed rapidly. Systemic availability varied from 11-86% (mean 33%). 4 Plasma levels correlated poorly with the acute effect on BP, raising the possibility of labetalol acting in a deep tissue compartment or alternatively an active metabolite contributing to its effect.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Collier J. G., Dawnay N. A., Nachev C., Robinson B. F. Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A. Br J Pharmacol. 1972 Feb;44(2):286–293. doi: 10.1111/j.1476-5381.1972.tb07265.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Farmer J. B., Kennedy I., Levy G. P., Marshall R. J. Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors. Br J Pharmacol. 1972 Aug;45(4):660–675. doi: 10.1111/j.1476-5381.1972.tb08125.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Homeida M., Jackson L., Roberts C. J. Decreased first-pass metabolism of labetalol in chronic liver disease. Br Med J. 1978 Oct 14;2(6144):1048–1050. doi: 10.1136/bmj.2.6144.1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Koch G. Combined alpha- and beta-adrenoreceptors blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):729–732. [PubMed] [Google Scholar]
- Loo J. C., Riegelman S. Assessment of pharmacokinetic constants from postinfusion blood curves obtained after I.V. infusion. J Pharm Sci. 1970 Jan;59(1):53–55. doi: 10.1002/jps.2600590107. [DOI] [PubMed] [Google Scholar]
- Louis W. J., Christophidis N., Brignell M., Vijayasekaran V., McNeil J., Vajda F. J. Labetalol: bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. Aust N Z J Med. 1978 Dec;8(6):602–609. doi: 10.1111/j.1445-5994.1978.tb04847.x. [DOI] [PubMed] [Google Scholar]
- Martin L. E., Hopkins R., Bland R. Metabolism of labetalol by animals and man. Br J Clin Pharmacol. 1976 Aug;3(4 Suppl 3):695–710. [PubMed] [Google Scholar]
- Richards D. A., Maconochie J. G., Bland R. E., Hopkins R., Woodings E. P., Martin L. E. Relationship between plasma concentrations and pharmacological effects of labetalol. Eur J Clin Pharmacol. 1977 Jan 3;11(2):85–90. doi: 10.1007/BF00562897. [DOI] [PubMed] [Google Scholar]